Cue Biopharma Proposes $60 Million IPO Terms
- Cue Biopharma has filed terms for its IPO of up to $60 million.
- The firm is preparing to enter Phase 1 trials for its lead candidate.
- I provide in-depth commentary in an expanded version of this article on my Seeking Alpha Marketplace IPO research service, IPO Edge. Visit to learn more.
Cue Biopharma (CUE) intends to sell up to $60 million in common stock in a ‘best efforts’ U.S. IPO, according to an amended S-1/A registration statement.
The firm is developing a pipeline of biologics that selectively modulate the immune system to potentially treat a variety of cancers and autoimmune diseases.
Cue has finalized an important collaboration agreement with Merck (MRK) but still has to enter Phase 1 trials for its lead candidate.
I provide in-depth commentary and opinion about this IPO opportunity on my Seeking Alpha Marketplace research service IPO Edge. Visit to learn more.
Cambridge, Massachusetts-based Cue Biopharma was founded to develop biologics for the treatment of cancer and autoimmune diseases.
For cancer, biologics utilize the body’s immune system, T-cells, to destroy cancer cells.
Management is headed by Daniel Passeri, who has been with the firm since September 2016 and was previously President and CEO of Curis (CRIS), an oncology drug development company.
The firm’s primary investors have provided $26.7 million in invested capital and include MDB Capital and associated persons (21.0% pre-IPO), Albert Einstein College (6.3%) and various other individuals.
Cue is developing a pipeline of biologic drugs with its lead candidate, CUE-101, targeting HPV-driven (Human Papilloma Virus) cancers.
Below is a chart showing the current status of the firm’s drug pipeline: